Clinical Trial Update: Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant therapy for high-risk or borderline resectable pancreatic cancer using surufatinib plus mFOLFIRINOX and a PD-1 inhibitor; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• PD-1 inhibitor
• Surufatinib (Surufatinib)
• mFOLFIRINOX

Snippet

Sponsor: Sun Yat-sen University | Conditions: Pancreatic Cancer Resectable | Phase 2 | Status: NOT_YET_RECRUITING